Skip to main
IMCR

Immunocore Holdings (IMCR) Stock Forecast & Price Target

Immunocore Holdings (IMCR) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 17%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

Immunocore Holdings is in a strong position as a commercial-stage biotechnology company with a diverse pipeline and a promising lead product, KIMMTRAK, for the treatment of unresectable or metastatic uveal melanoma (mUM). The company's robust post-progression survival data and favorable safety profile support its continued growth and potential expansion into new therapeutic areas. Additionally, the company's late-stage readouts in oncology, infectious disease, and autoimmune pipelines, as well as its focus on expanding its patient population and revenue growth, make it a promising investment opportunity with potential for upside in the future.

Bears say

Immunocore Holdings is a biotechnology company facing risks related to its diverse pipeline and potential challenges in obtaining regulatory approvals for its drugs. The company's financials may also be impacted by the need for additional funds to support clinical trials and commercialization efforts. With a low probability of success for its lead products, there is a significant downside risk for investors in the short term.

Immunocore Holdings (IMCR) has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 17% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Immunocore Holdings and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Immunocore Holdings (IMCR) Forecast

Analysts have given Immunocore Holdings (IMCR) a Buy based on their latest research and market trends.

According to 6 analysts, Immunocore Holdings (IMCR) has a Buy consensus rating as of Jun 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $59.83, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $59.83, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Immunocore Holdings (IMCR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.